|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
JULY 26, 2004
Taking Encysive To Heart  Buying into a company that bets heavily on a single new drug is dicey. But it's a risk worth taking in the case of Encysive Pharmaceuticals (ENCY
), says Mark Monane of brokerage Needham. Encysive is in the third and final phase of bringing to market a pill for pulmonary arterial hypertension. The disease forces the heart to work too hard to pump blood through constricted arteries into the lungs, causing shortness of breath and exhaustion. Untreated, it results in heart failure and death about four years from diagnosis. An estimated 50,000 people in the U.S. are afflicted.
The most effective current treatment is a drug called Flolan, which is pumped round the clock through a tube into the chest. The cost: $100,000 a year. Swiss company Actelion recently came to market with a twice-a-day pill, for which it charges $30,000 a year. Encysive's pill, Thelin, is swallowed once a day. In trials so far, Encysive says Thelin users were able to walk significantly farther in treadmill tests than untreated patients. Monane, whose firm was an underwriter for Encysive, expects more data to come out by early next year and lift the stock from its recent 7.32 toward his 12-month target of 14. He says Encysive will be able to sell the drug for $25,000 a year, making its first profit in 2006. Deutsche Bank (DB ) analyst Jennifer Chao rates the stock a buy with a target of 16. Gene Marcial will be back next week. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By David Henry
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2004, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version
